ライフサイエンスコーパス: 5-HT(3) receptor

1 ory responses through ligand-gated channels (5-HT3 receptors).

2 loop and the critical role of Pro 8* in the 5-HT3 receptor.

3 ding preferentially to the open state of the 5-HT3 receptor.

4 em acts by causing open-channel block of the 5-HT3 receptor.

5 sis (CoMFA) is applied to antagonists of the 5-HT3 receptor.

6 r is the best-characterized heteropentameric 5-HT3 receptor.

7 se and differential expression of 5-HT1A and 5-HT3 receptors.

8 neuronal activation in the DVC by activating 5-HT3 receptors.

9 Extrinsic nerves are activated by 5-HT3 receptors.

10 ction is not clear and may involve hindbrain 5-HT3 receptors.

11 ze a 5-HT-containing pathway which activates 5-HT3 receptors.

12 holecystokinin A receptors and serotonin via 5-HT3 receptors.

13 s high-affinity CCK-A receptors also express 5-HT3 receptors.

14 nly high- or low-affinity CCK-A receptors or 5-HT3 receptors.

15 may also be responsive to serotonin through 5-HT3 receptors.

16 nd 31 units, respectively, by activating the 5-HT3 receptors.

17 and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors.

18 receptor subunit (5-HT3A) yields functional 5-HT3 receptors.

19 ediated by 5-HT in the colonic mucosa and by 5-HT3 receptors.

20 alterations in the neuronal distribution of 5-HT3 receptors.

21 ch activates an inhibitory pathway involving 5-HT3 receptors.

22 e nerve responses apparently by blocking the 5-HT3 receptors.

23 at expression of gLTD involves activation of 5-HT(3) receptor.

24 One of these is the ionotropic 5-HT(3) receptor.

25 nt determinant of agonist recognition at the 5-HT(3) receptor.

26 ient kinetic investigations of the serotonin 5-HT(3) receptor.

27 ed the highest affinity (pK(i) > 10) for the 5-HT(3) receptor.

28 f 5-HT receptors, including the 5-HT type-3 (5-HT3) receptors.

29 s multimodal subunit-dependent antagonism of 5-HT(3) receptors.

30 gonist, is a potent competitive inhibitor of 5-HT(3) receptors.

31 actions on 5-HT-evoked currents mediated by 5-HT(3) receptors.

32 that was in part mediated by 5-HT acting via 5-HT(3) receptors.

33 smission via a facilitatory action at spinal 5-HT(3) receptors.

34 ic afferent endings via both 5-HT(3) and non-5-HT(3) receptors.

35 me superfamily, including GABA(A), nACh, and 5-HT(3) receptors.

36 atal nicotinic exposure in rat pups: role of 5-HT(3) receptors.

37 y prevented by functional blockade of spinal 5-HT(3) receptors.

38 onses elicited by systemic injections of the 5-HT(3) receptor (5-HT(3)R) agonists such as phenylbigua

39 The molecular makeup of the serotonin 5-HT(3) receptor (5-HT(3)R) channel was investigated in

40 The serotonin 5-HT(3) receptor (5-HT(3)R) is a member of the Cys-loop

41 The serotonin 5-HT(3) receptor (5-HT(3)R) is a member of the cys-loop

42 sal enterochromaffin cells and activation of 5-HT(3) receptors (5-HT(3)Rs) on neurons in the gut wall

43 ass of negative allosteric modulators of the 5-HT(3) receptors (5-HT(3)Rs).

44 The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) redu

45 permeability seen in native and recombinant 5-HT3 receptor (5-HT3R) channels, we reported previously

46 The kinetics of desensitization of the 5-HT3 receptor (5-HT3R)-gated ion channel were investiga

47 spinal dorsal horn via activation of spinal 5-HT3 receptors (5-HT3Rs).

48 ave the capacity to synthesize two different 5-HT3 receptors, 5-HT3A+/3B- and 5-HT3A+/3B+ receptors.

49 Using a simplified model of the pore of the 5-HT(3) receptor (5HT3R) which restrains the backbone st

50 of the 5-HT3A receptor subunit rendered the 5-HT3 receptor 70-fold more sensitive to serotonin and p

51 st channel conductance displayed by neuronal 5-HT3 receptors (9-17 pS).

52 The 5-HT(3) receptor, a pentameric ligand-gated ion channel

53 e activity of this compound class verses the 5-HT(3) receptor, a structural homologue of the alpha7 n

54 ond messenger pathways, or to the ionotropic 5-HT3 receptor, a non-selective cation channel that medi

55 bout PKC modulation of the serotonin type 3 (5-HT3) receptor, a ligand-gated membrane ion channel tha

56 nthesize at least two structurally different 5-HT(3) receptors: a heteromeric 5-HT(3A/3B) receptor an

57 I cells activates gustatory nerve fibers via 5-HT3 receptors, accounting for a significant proportion

58 m, these results suggest that stimulation of 5-HT3 receptors activates an intracellular signalling ca

59 ate in the inhibition of aggression, whereas 5-HT3 receptor activation facilitates aggression, the au

60 This excitatory response to 5-HT3 receptor activation may be partly a direct postsyn

61 tamine (5-HT)1A receptors and facilitated by 5-HT3 receptor activation.

62 response was regulated by serotonin Type 3 (5-HT(3)) receptor activity and correlated with altered 5

63 of descending serotonergic pathways or tonic 5-HT3 receptor activity in maintaining hypersensitivity

64 Likewise, posterior IC administration of the 5-HT(3) receptor agonist m-chlorophenylbiguanide (mCPBG)

65 ptor by intrathecal injection of a selective 5-HT(3) receptor agonist, SR57227, induced spinal glial

66 icrog kg(-1)) and PBG (100 microg kg(-1)), a 5-HT(3) receptor agonist, stimulated nine ischaemically

67 T(3B) with 5-HT(3A) modified the duration of 5-HT(3) receptor agonist-induced responses, linearized t

68 ione (DNQX) on the excitatory actions of the 5-HT3 receptor agonist 1-phenylbiguanide (PBG) were stud

69 A 5-HT3 receptor agonist CPBG (1 microM), mimicked the unm

70 that phenyldiguanide (later recognized as a 5-HT3 receptor agonist) stimulated the firing of C-fibre

71 This initial response was mimicked by the 5-HT3 receptor agonist, 2-methyl-5-HT, whereas 5-methoxy

72 sed with the 5-HT1A receptor agonist and the 5-HT3 receptor agonist, m-chlorophenyl-biguanide (mCPBG;

73 retic application of PBG, a highly selective 5-HT3 receptor agonist, significantly increased activity

74 2-methylserotonin (100 microg kg-1, i.a.), a 5-HT3 receptor agonist, stimulated eleven of twelve affe

75 eceptor motions during binding of a range of 5-HT(3) receptor agonists and antagonists.

76 In contrast, 5-HT(3) receptor agonists increased sEPSCs on a minority

77 5-HT(3) receptor agonists increased the firing rate of T

78 5-HT(3) receptor agonists increased the frequency, but n

79 These findings suggest that tachyphylaxis to 5-HT(3) receptor agonists may be due to the desensitizat

80 r antagonist ondansetron and mimicked by the 5-HT(3) receptor agonists SR5227 and mCPBG.

81 5-HT(3) receptor agonists stimulate intestinal motility,

82 milar before and after the injections of the 5-HT(3) receptor agonists.

83 pressure and cardiac output elicited by the 5-HT(3)-receptor agonists, phenylbiguanide (100 microg/k

84 With the exception of the 5-HT3 receptor, all of the cloned serotonin receptors be

85 ude that colonic sensory neurones expressing 5-HT(3) receptors also functionally express the receptor

86 Functional down-regulation of 5-HT(3) receptors also occurs in the post-infected anima

87 Neuronal 5-HT3 receptors also display a permeability to calcium i

88 genetic or pharmacological disruption of the 5-HT(3) receptor, an excitatory serotonin-gated ion chan

89 n the basis of its ability to inactivate the 5-HT3 receptor, an excitatory serotonin-gated ion channe

90 mechanisms underlying the activation of the 5-HT(3) receptor and its contribution to facilitation of

91 ation after mTBI, direct 5-HT effect through 5-HT(3) receptors and indirectly through upregulation of

92 sion of the functional 5-HT3A subunit of the 5-HT3 receptor and the central CB1 cannabinoid receptor

93 erents, mainly through direct stimulation of 5-HT3 receptors and that the action of 5-HT on these aff

94 ether gustatory afferents express functional 5-HT3 receptors and, if so, whether these receptors play

95 notropic glycine receptor, GABA(A) receptor, 5-HT(3) receptor, and nAChR subunits contain a pair of h

96 face at both homomeric and heteromeric human 5-HT(3) receptors, and explain why the competitive pharm

97 e receptors, GABA(A) receptors, serotonin-3 (5-HT(3)) receptors, and glutamate-gated chloride ion cha

98 -application of 5-HT (300 microM), acting at 5-HT3 receptors, and ACh (3 mM) or ATP (1 mM) were addit

99 of disgust and taste avoidance by selective 5-HT(3) receptor antagonism/agonism in the posterior (gr

100 sponses to 2-methyl-5-HT were blocked by the 5-HT(3) receptor antagonist alosetron (2 x 10(-7) M), wh

101 etic risk radiation therapy should receive a 5-HT(3) receptor antagonist before each fraction and for

102 The 5-HT(3) receptor antagonist granisetron (1 microM) and t

103 Treatment of ganglia with the 5-HT(3) receptor antagonist MDL 72222 (0.5 microM) durin

104 Pretreatment of ganglia with the 5-HT(3) receptor antagonist ondansetron (0.4 microm) alo

105 TS-TH-EGFP neurons, an effect blocked by the 5-HT(3) receptor antagonist ondansetron and mimicked by

106 to treat morphine dependence, also exhibited 5-HT(3) receptor antagonist properties.

107 response to acetylcholine was blocked by the 5-HT(3) receptor antagonist renzapride with a similar IC

108 Pretreatment of ganglia with the 5-HT(3) receptor antagonist tropisetron (0.5 microM) com

109 or any highly emetic agents should receive a 5-HT(3) receptor antagonist, dexamethasone, and a neurok

110 etron (300 microg kg(-1), I.V.), a selective 5-HT(3) receptor antagonist, eliminated the afferent's r

111 Intracranial administration of the 5-HT(3) receptor antagonist, ondansetron (OND), to the p

112 The 5-HT(3) receptor antagonist, ondansetron, has been shown

113 tion and predict therapeutic response to the 5-HT(3) receptor antagonist, ondansetron.

114 Aprepitant, a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone a

115 kg-1, i.v.), or treatment with the selective 5-HT3 receptor antagonist alosetron (30 microg kg-1, i.v

116 Although tropisetron is a 5-HT3 receptor antagonist and an alpha7nAChR partial ago

117 1) receptor antagonist in conjunction with a 5-HT3 receptor antagonist and corticosteroid in patients

118 Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well tole

119 Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tole

120 isetron; 500 ng), or were coinfused with the 5-HT3 receptor antagonist and the 5-HT2A/2C receptor ago

121 o 3.8 +/- 1.1 spikes s(-1)) by the selective 5-HT3 receptor antagonist granisetron.

122 coefficient = 1.8) that were blocked by the 5-HT3 receptor antagonist ondansetron (IC50 = 103 pM) an

123 The 5-HT3 receptor antagonist ondansetron is a good candidat

124 led to do so in Tph1(-/-) colon; and (9) the 5-HT3 receptor antagonist ondansetron, which reduced CMM

125 ivity effect of intrathecal injection of the 5-HT3 receptor antagonist ondansetron.

126 otetralin (DPAT; 0.1 mg/kg and 0.3 mg/kg) or 5-HT3 receptor antagonist tropisetron (0.3 mg/kg) treatm

127 d Fos-LI in the DVC of ondansetron (1 mg/kg; 5-HT3 receptor antagonist) and vehicle-treated rats foll

128 Rats were infused with the 5-HT3 receptor antagonist, 3-tropanyl-indole-3 carbonyla

129 A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommen

130 combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.

131 ICS205-930 (1 microM), a 5-HT3 receptor antagonist, completely blocked the 5-HT-i

132 -HT response was completely abolished by the 5-HT3 receptor antagonist, granisetron (0.5 mg kg-1).

133 njection of tropisetron (200 microg kg-1), a 5-HT3 receptor antagonist, significantly attenuated the

134 and 5-HT4 receptor antagonists, but not by a 5-HT3 receptor antagonist.

135 urthermore, this mutation also converted the 5-HT3 receptor antagonist/very weak partial agonist, apo

136 rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the pr

137 f ondansetron, a selective serotonin type-3 (5-HT3) receptor antagonist, attenuates cholecystokinin (

138 rotonin and this effect was blocked with the 5-HT3-receptor antagonist ondansetron.

139 ) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the prevention of acute

140 5-HT(3) receptor antagonists have proved effective in su

141 5-HT(3) receptor antagonists reduce symptoms of IBS clin

142 ative efficacy of the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonists.

143 wide dynamic range neurons are inhibited by 5-HT3 receptor antagonists in rats following spinal nerv

144 whisking frequencies, and selective 5-HT2 or 5-HT3 receptor antagonists suppress this rhythmic firing

145 Unilateral infusion of selective 5-HT2 or 5-HT3 receptor antagonists suppresses ipsilateral whiski

146 by DPPIV inhibition or by cholecystokinin or 5-HT3 receptor antagonists, but was inhibited by atropin

147 nged efficacy, and acts synergistically with 5-HT3 receptor antagonists.

148 Given that both GABA(A) and 5-HT(3) receptors are involved in the generation of DRRs

149 5-HT(3) receptors are pentameric ligand-gated ion channe

150 Probably the most studied modulators of 5-HT(3) receptors are the high affinity competitive 'set

151 5-Hydroxytryptamine type 3 (5-HT(3)) receptors are cation-selective Cys loop recepto

152 oline (nACh) and 5-hydroxytryptamine type 3 (5-HT(3)) receptors are cation-selective ion channels of

153 5-Hydroxytryptamine type 3 (5-HT(3)) receptors are ligand-gated ion channels that pl

154 the modulation of interoceptive circuits, as 5-HT3 receptors are located abundantly on sensory pathwa

155 The 5-HT3 receptors are serotonin-gated ion channels that ph

156 5-hydroxytryptamine type 3 (5-HT3) receptors are cation-selective transmitter-gated

157 5-hydroxytryptamine type 3 (5-HT3) receptors are members of the Cys-loop receptor su

158 Serotonin type 3 (5-HT3) receptors are members of the pentameric Cys-loop

159 be the role of two residues in loop A of the 5-HT3 receptor: Asn128 and Glu129.

160 gle-channel conductance of human recombinant 5-HT3 receptors assembled as homomers of 5-HT3A subunits

161 ptors at a concentration up to 100 mum or on 5-HT(3) receptors at a concentration up to 10 mum.

162 ain targets but that allosterically modulate 5-HT(3) receptors at clinically relevant concentrations.

163 reas was prepared and tested for 5-HT(4) and 5-HT(3) receptor binding, 5-HT(4) receptor agonism in th

164 us, the data support a modified model of the 5-HT3 receptor binding site and show that loop A plays a

165 143, Tyr153, and Tyr234), which dominate the 5-HT3 receptor binding site.

166 We report that recombinantly expressed 5-HT3 receptor binding sites are reduced by chronic expo

167 sisted for 8 weeks PI and was susceptible to 5-HT(3) receptor blockade.

168 hese physiologic data, the effects of spinal 5-HT3 receptor blockade on behavioral hypersensitivity a

169 Second, we examined the effects of hindbrain 5-HT3 receptor blockade on suppression of intake by syst

170 The efficacy of a new 5-HT3 receptor blocking drug in the treatment of the dia

171 In the present study, activation of spinal 5-HT(3) receptor by intrathecal injection of a selective

172 O-CNB-5HT does not activate the 5-HT(3) receptor by itself, nor does it modulate the res

173 time of the recombinant and native neuronal 5-HT(3) receptors by 3- to 6-fold.

174 The inhibition of 5-HT(3) receptors by AEA may contribute to its physiolog

175 work not only unveils the mechanism by which 5-HT3 receptors can reach their axonal localization requ

176 Thus, presynaptic 5-HT3 receptors containing the 5-HT3B subunit might be p

177 R-mApple cells were highly co-expressed with 5-HT3 receptor-containing neurons within the cortex and

178 These observations suggest that 5-HT(3) receptor density at the steady state regulates r

179 Also, 5-HT3 receptor density was greater in H-Agg hamsters wit

180 LTP of sympathetic ganglia is 5-HT(3) receptor-dependent and has been shown to require

181 el lining, but may play an important role in 5-HT3 receptor desensitization.

182 n-selective 5-HT agonist devoid of action at 5-HT3 receptors, did not (n = 18).

183 However, pre-blockade of 5-HT3 receptors eliminated the influence of the antibody

184 ed bladder afferent firing predominantly via 5-HT(3) receptors expressed on afferent terminals.

185 ptors were not detected in mouse urothelium, 5-HT(3) receptors expressed on bladder sensory neurons p

186 eceptor activity and correlated with altered 5-HT(3) receptor expression.

187 have mutated 21 residues in or close to the 5-HT(3) receptor F-loop (Ile(192) to Gly(212)) to Ala or

188 l our results are consistent with a flexible 5-HT(3) receptor F-loop with two regions that have speci

189 mportant aspects of the mechanistic basis of 5-HT(3) receptor function and modulation by drugs remain

190 he molecular basis for alcohol modulation of 5-HT(3) receptor function has not been determined.

191 tanding the structural mechanisms underlying 5-HT(3) receptor function.

192 udy the mechanism of alcohol potentiation of 5-HT3 receptor function and to analyse effects of alcoho

193 A human recombinant homo-oligomeric 5-HT3 receptor (h5-HT3A) expressed in a human embryonic

194 alter the density of serotonergic fibers or 5-HT3 receptor immunoreactivity or spinal tissue content

195 These data support a role for 5-HT(3) receptors in adolescent cocaine-induced aggressi

196 ioned disgust reactions, while activation of 5-HT(3) receptors in the anterior IC are involved in the

197 These results suggest that activation of 5-HT(3) receptors in the posterior IC is important for t

198 anaesthetized rats investigated the role of 5-HT3 receptors in modulating vagal afferent evoked acti

199 tribution consistent with the involvement of 5-HT3 receptors in modulation of both presynaptic releas

200 s, that 5-HT2A receptors are segregated from 5-HT3 receptors in the macaque cerebral cortex.

201 ventromedial medulla and the contribution of 5-HT3 receptors in the trigeminal nucleus caudalis (Vc),

202 Pharmacological blockade of 5-HT3 receptors in vivo or genetic deletion of the 5-HT3

203 amine2A receptors and the ion-channel gating 5-HT3 receptors, in cortical neuron types, which control

204 receptor were limited, the broad effects of 5-HT3 receptor included repetitive and impulsive element

205 the EC(50) of 5-HT reduced as the density of 5-HT(3) receptors increased, suggesting an effect of rec

206 This is confirmed for 5-HT3 receptor-induced contractions in the guinea pig il

207 d butanol (ButOH) had similar effects on the 5-HT3 receptor-induced current.

208 ugh serotonin, acting on facilitatory spinal 5-HT3 receptors, influences the final expression of DNIC

209 tive and that the contribution of peripheral 5-HT(3) receptors involves a novel complement of primary

210 The 5-HT(3) receptor is a member of the Cys-loop family of l

211 The 5-HT(3) receptor is an important ligand-gated ion channe

212 indicating that the 5-HT(3B) subunit of the 5-HT(3) receptor is expressed in DRG and suggest that se

213 Thus, it is believed that a native neuronal 5-HT(3) receptor is multimeric similar to the related ac

214 at activation of both peripheral and central 5-HT(3) receptors is pronociceptive and that the contrib

215 The 5-hydroxytryptamine(3) (5-HT(3)) receptor is a member of a superfamily of ligand

216 The type 3 serotonin (5-HT(3)) receptor is the only ligand-gated ion channel r

217 tivity because the endogenous ligand for the 5-HT3 receptor is a hydroxylated derivative of tryptopha

218 The 5-HT3 receptor is a member of the Cys-loop ligand-gated

219 The 5-HT3 receptor is a transmitter-gated ion channel of the

220 The type 3 serotonin (5-HT3) receptor is the only ligand-gated ion channel rec

221 combined with a new model of the nonliganded 5-HT3 receptor, lead to a mechanistic explanation of the

222 ing binding of 5-HT and different classes of 5-HT(3) receptor ligands.

223 trogradely labelled from the colon displayed 5-HT(3) receptor-like immunoreactivity.

224 he lumbar DRG, where they were processed for 5-HT(3) receptor-like immunoreactivity.

225 These data demonstrate that 5-HT3 receptors located in the medial NTS participate in

226 ity of high-resolution structures of a mouse 5-HT(3) receptor, many important aspects of the mechanis

227 open the possibility that distinct types of 5-HT(3) receptors may be involved in perception and/or p

228 These results suggest that activation of 5-HT(3) receptors may be involved in the production of C

229 partmentalized structural composition of the 5-HT3 receptor may be the basis of functional diversity

230 hetic afferents, at least in part, through a 5-HT(3) receptor mechanism.

231 cardiac afferents during ischaemia through a 5-HT(3) receptor mechanism.

232 ents through a serotonin receptor (subtype 3,5-HT3 receptor) mechanism, before treatment with the ant

233 Therefore, we hypothesized that 5-HT3 receptors mediate CCK-induced Fos-LI in the dorsal

234 To determine the relevant sites for 5-HT3 receptor mediated transmission in this region, we

235 nica muscularis mucosae (TMM) assay, and for 5-HT(3) receptor-mediated functional antagonism in the B

236 may play a role in reshaping the efficacy of 5-HT(3) receptor-mediated synaptic transmission.

237 -CNB-5HT released free serotonin that evoked 5-HT(3) receptor-mediated whole-cell currents in NIE-115

238 Ethanol can potentiate serotonin type 3 (5-HT(3)) receptor-mediated responses in various neurons

239 This study suggests that alcohols potentiate 5-HT3 receptor-mediated current by both increasing the r

240 Here, we show that PKC potentiated 5-HT3 receptor-mediated current in Xenopus oocytes expre

241 5-HT3 receptor-mediated ion current was recorded from NC

242 ically, in the setting of tissue injury, the 5-HT(3) receptor mediates activation of nociceptors but

243 The 5-HT(3) receptor mediates fast serotonergic neurotransmi

244 The exact location of 5-HT3 receptors mediating this action is not clear and m

245 iously, we have shown that serotonin type-3 (5-HT3) receptor mediation of suppression of food intake

246 the mid-to-caudal regions of the NTS and AP, 5-HT3 receptors most significantly mediate neuronal acti

247 Various non-5-HT(3) receptor mRNA transcripts are expressed in mouse

248 ung-specific jugular neurons did not express 5-HT3 receptor mRNA but frequently expressed 5-HT1 or 5-

249 trogradely labelled from the lung, expressed 5-HT3 receptor mRNA.

250 a broad range of compounds that modulate the 5-HT(3) receptor, not through the orthosteric site but b

251 gonists may be due to the desensitization of 5-HT(3) receptors on cardiopulmonary afferents rather th

252 ferents from the colon and the expression of 5-HT(3) receptors on their cell bodies in the dorsal roo

253 T to inappropriate sites in IBS may activate 5-HT3 receptors on extrinsic afferent fibers and motor n

254 lucose regulates the density and function of 5-HT3 receptors on gastric vagal afferent neurones.

255 evidence shows mRNA expression of 5-HT2C and 5-HT3 receptors on GLP-1-producing preproglucagon (PPG)

256 th the antibody in another group, we blocked 5-HT3 receptors on sensory nerve endings with tropisetro

257 ine have been defined as partial agonists of 5-HT3 receptors on the basis of macroscopic measurements

258 c) tastants and this released 5-HT activates 5-HT3 receptors on the gustatory nerves.

259 intestinal enterochromaffin cells activates 5-HT3 receptors on vagal afferent fibres to mediate lumi

260 al enterochromaffin cells, which acts on the 5-HT3 receptors on vagal afferent fibres to stimulate va

261 rt latency, transient excitation mediated by 5-HT3 receptors, or a delayed onset, more prolonged effe

262 5-HT(3) receptors participate in vagal afferent feedback

263 This raises the possibility that 5-HT3 receptors participating in sympathetic, parasympat

264 These data suggest that the role 5-HT(3) receptors play in bladder afferent signalling wa

265 oocytes is sufficient to reconstitute native 5-HT(3) receptor properties.

266 sodium channel beta2 subunits or ionotropic 5-HT(3) receptors, proteins with no overt relationship t

267 receptors in vivo or genetic deletion of the 5-HT3 receptors reduces taste nerve responses to acids a

268 Inhibition of 5-HT(3) receptors releases acetylcholine, the endogenous

269 s to recommend the two-drug combination of a 5-HT3 receptor serotonin antagonist and dexamethasone.

270 The three-drug combination of a 5-HT3 receptor serotonin antagonist, dexamethasone, and

271 Blockade of serotonin (5-HT(3)) receptor signalling in the NTS by either the ch

272 s of muscarinic, AMPA, NMDA, GABAA, ATP, and 5-HT3 receptors, spontaneous and evoked postsynaptic cur

273 edial medulla (RVM) in the brainstem and the 5-HT(3) receptor subtype in the spinal dorsal horn are i

274 o increased apparent desensitization of both 5-HT(3) receptor subtypes.

275 T(3)-receptor subunits have been cloned: the 5-HT(3)-receptor subunit A (5-HT(3A)) and the 5-HT(3)-re

276 -HT(3)-receptor subunit A (5-HT(3A)) and the 5-HT(3)-receptor subunit B (5-HT(3B)).

277 Here we describe a new class of 5-HT3-receptor subunit (5-HT3B).

278 There are five 5-HT(3) receptor subunits (A-E), and all functional rece

279 conserved among 5-hydroxytryptamine type 3 (5-HT(3)) receptor subunits and many other subunits of th

280 Two 5-HT(3)-receptor subunits have been cloned: the 5-HT(3)-

281 Uniquely, 5-HT3 receptor subunits (5-HT3A and 5-HT3B) possess a po

282 Two 5-HT3 receptor subunits have been cloned, subunit A (5-H

283 e of the vestibule binding site to the human 5-HT(3) receptor, suggesting a common mechanism of modul

284 Thus, the prevalent form of 5-HT3 receptor synthesized within the CNS lacks the 5-HT

285 s mesenteric afferents by a direct action on 5-HT3 receptors that are present on vagal mucosal affere

286 Drugs that selectively antagonize 5-HT(3) receptors (the "setrons") are the current gold s

287 final sigma-Conotoxin inactivates the 5-HT3 receptor through competitive antagonism and is a h

288 is a specific competitive antagonist of the 5-HT3 receptor; thus, alphaS-RVIIIA defines a novel fami

289 ges in the extracellular domain of the human 5-HT(3) receptor to identify intrareceptor motions durin

290 egulate directly the function and binding of 5-HT3 receptors to ondansetron.

291 s result is explained by the localization of 5-HT(3) receptor transcripts to a previously uncharacter

292 eurons was used to investigate expression of 5-HT(3) receptors using single cell RT-PCR, while sensor

293 y of the compound for kinetic studies of the 5-HT(3) receptor was demonstrated.

294 d that the interaction of diltiazem with the 5-HT3 receptor was well described by a bimolecular react

295 Whilst 5-HT(3) receptors were not detected in mouse urothelium,

296 sponses were reduced, and that the remaining 5-HT3 receptors were hypersensitive.

297 nts is activated directly via stimulation of 5-HT3 receptors, while another population responds to 5-

298 action of L-type Ca2+ channel antagonists on 5-HT3 receptors, whole-cell voltage clamp electrophysiol

299 Consequently, 5-HT(3) receptors with different properties might be pre

300 fibers, serotonin content and the levels of 5-HT3 receptors within the spinal cord at this time poin